Clinical Trials Browser

Phase 2 × Urinary Bladder Neoplasms × Trastuzumab × Clear all

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT01828736 2017-02-06

CVH-CT02

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00005831 2013-01-14

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Phase 2 Completed

Urinary Bladder Neoplasms